Eligibility criteria {10}
cancers, neuropathic symptoms, cancer, gabapentinPatients, gynecological malignancies, peripheral neuropathy, allergic or anaphylactic reaction
ONCOLOGY, CANCER, CANCERS, PERIPHERAL NEUROPATHY
All the following criteria must be met for enrolment:Age ≥ 18 yearsPlanned to receive paclitaxel for breast, lung, and gynecological malignancies, either in the adjuvant or neoadjuvant settingPatients planned for four or more cycles of paclitaxel therapyOvarian cancer: 135–175 mg/mBreast cancer: 175 mg/mCervical cancer/uterine cancer: 175 mg/mLung cancer: 175–200 mg/mWeekly chemotherapy in above-mentioned cancers: 60–80 mg/m.Eastern Cooperative Oncology Group (ECOG) performance status 0–2Planned to initiate paclitaxel within 14 days of randomizationPatient willing to participate in the study and to provide written informed consentPatients with any of the following will be excluded from the trial:Evidence of pre-existing peripheral neuropathy on clinical examination or nerve conduction studiesPrior therapy with taxanes (paclitaxel or docetaxel)Conditions that impair neurocognitive function or may complicate evaluation during study treatmentConcurrent, prior (within 1 month of chemotherapy initiation), or planned use of agents used for neuropathic symptoms (example: tricyclic anti-depressants, pregabalin, duloxetine, etc.)History of allergic or anaphylactic reaction with gabapentinPatients already receiving oral gabapentin for other indicationsConcurrent illnesses that may hinder a patient’s ability to undergo protocol-mandated procedures with reasonable safetyPregnant or lactating women